Rosetta Licenses microRNA Sequences from Max Planck for Dx Development | GenomeWeb
NEW YORK (GenomeWeb News) - Rosetta Genomics has licensed from the Max Planck Society rights to patents covering “potentially hundreds” of human microRNA sequences for use in diagnostic applications, the company said.
 
Rosetta said it will add the sequences to its microRNA database, where they will provide the company with additional biomarker candidates for its diagnostic-development programs.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.